Table 3 The HCV RNA undetectable rates and adverse effects among time-points
Parameters | ECS(n = 94) | DNV (n = 84) | All (n = 178) | P |
|---|---|---|---|---|
HCV RNA undetectable | ||||
4-week treatment | 84 (88.42%) | 61 (72.62%) | 145 (81.46%) | 0.004 |
At the end of treatment | 94(100.00%) | 82 (97.62%) | 176 (94.25%) | 0.132 |
SVR12 | 94(100.00%) | 84(100.00%) | 178 (100.00%) | 1.000 |
Adverse effects | 0.331 | |||
No | 92 (97.87%) | 80 (95.24%) | 172 (96.63%) | |
Yes | 2 (2.13%) | 4 (4.76%) | 6 (3.37%) |